Amgen and Gilead deliver lacklustre early clinical results with AMG 355 and denikitug respectively.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
JNJ-95566692 enters phase 1, with Qilu neck and neck.
Three private biotechs enter clinical trials, one targeting KRAS.
But PFS data are lacking, and there are questions about first and second-line plans.
But the company still has a lot to prove with ERAS-0015.
The company will start three phase 3 trials of its G12D project this year.
